Table 4.
Hypertension and/or diabetes, and CKD status.
| Clinical features | CKD patients | Non CKD patients | Total | P |
|---|---|---|---|---|
|
JNC 7 guidelines All patients (BP in mmHg) |
||||
| Normal, < 120 and < 80 | 52 (27.5) | 143 (43.2) | 195 (35.5) | 0.0005 |
| PreHBP, 120–139 or 80–89 | 32 (16.9) | 56 (19.6) | 88 (16.9) | 0.5 |
| Stage 1, 140–159 or 90–99 | 38 (20.1) | 72 (21.8) | 110 (21.2) | 0.7 |
| Stage 2, ≥ 160 or ≥ 100 | 67 (35.4) | 60 (18.1) | 127 (24.4) | <0.0001 |
| Hypertensives | ||||
| Antihypertensive drugs | ||||
| none | 1 (1.1) | 11 (10.6) | 22 (11.2) | 0.01 |
| Any treatment | 89 (98.9) | 93 (89.4) | 182 (88.8) | 0.01 |
| 1 antihypertensive | 62 (71.3) | 60 (57.7) | 122 (62.2) | 0.06 |
| mean antihypertensive drugs | 1.28 ± 0.5 | 1.22 ± 0.6 | 1.25 ± 0.6 | 0.1 |
| ACEI* | 21 (23.3) | 33 (31.7) | 54 (27.7) | 0.2 |
| Normal, < 120 and < 80 | 7 (5.2) | 17 (10.0) | 24 (7.9) | 0.1 |
| High normal, 120–139 or 80–89 | 22 (16.4) | 21 (12.4) | 43 (14.1) | 0.4 |
| Stage 1, 140–159 or 90–99 | 38 (28.4) | 72 (42.4) | 110 (36.2) | 0.01 |
| Stage 2, ≥ 160 or ≥ 110 | 67 (50.0) | 60 (35.3) | 127 (41.8) | 0.01 |
| < 130/80 | 8 (6.0) | 21 (12.4) | 29 (9.5) | 0.09 |
| < 125/75 | 4 (3.0) | 11 (6.5) | 15 (4.9) | 0.2 |
| Serum glucose level (mg/dl) | ||||
| Diabetics | ||||
| < 110 | 14 (12.8) | 17 (9.8) | 31 (11.0) | 0.5 |
| 110–125 | 8 (7.3) | 12 (6.9) | 20 (7.1) | 0.9 |
| ≥ 126 | 87 (79.8) | 145 (83.3) | 232 (82.0) | 0.5 |
| ≥ 180 | 45 (41.3) | 91 (52.3) | 136 (48.1) | 0.09 |
Values expressed as numbers and proportions in parentheses or mean ± SD, as appropriate.
CKD is defined either kidney damage (proteinuria ≥ 300 mg/day) and/or kidney function (< 60 ml/min/1.73 m2).
Percentages based on responding number, not total participant number.
ACEI: Angiotensin-Converting Enzyme Inhibitors. PreHTN = Prehypertension.